Compare RMTI & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RMTI | NEUP |
|---|---|---|
| Founded | 1994 | 1996 |
| Country | United States | United States |
| Employees | 300 | 8 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.7M | 23.1M |
| IPO Year | 2022 | N/A |
| Metric | RMTI | NEUP |
|---|---|---|
| Price | $0.66 | $4.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.00 | ★ $21.00 |
| AVG Volume (30 Days) | ★ 316.2K | 62.7K |
| Earning Date | 05-07-2026 | 05-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $69,258,000.00 | N/A |
| Revenue This Year | $8.64 | N/A |
| Revenue Next Year | $8.44 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.60 | $3.65 |
| 52 Week High | $2.10 | $21.31 |
| Indicator | RMTI | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 35.53 | 35.82 |
| Support Level | $0.60 | $3.91 |
| Resistance Level | $1.00 | $4.56 |
| Average True Range (ATR) | 0.04 | 0.30 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 26.60 | 26.67 |
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.